Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 66 of 99

  1. PC14586

    PMV Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  2. PCS499

    Processa Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  3. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  4. PCV-LITE-I

    Teva Pharma GmbH

    Pneumococcal infection

    phase 1 other active

    1 trial

  5. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  6. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  7. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  8. PDY17892

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 1 other active

    1 trial

  9. PDY18058

    Sanofi-aventis Healthcare Pty Ltd

    Immuun system diseases

    phase 1 other active

    1 trial

  10. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy

    phase 1 small molecule completed

    1 trial

  12. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Cholangiocarcinoma Non-resectable

    phase 1 small molecule terminated

    1 trial

  13. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Solid Tumor

    phase 1 small molecule completed

    2 trials

  14. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    NSCLC

    phase 1 small molecule completed

    1 trial

  15. PEGylated recombinant candida urate oxidase

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  16. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  17. PEGylated recombinant human interferon alpha-2b injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B, Chronic

    phase 1 small molecule active

    1 trial

  18. PENNVAX-B

    INOVIO PHARMACEUTICALS, INC.

    HIV-1 Infection

    phase 1 mab completed

    1 trial

  19. PERSEVERANCE EU

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  20. PF-03715455

    Pfizer

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. PF-05190457

    Pfizer

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  22. PF-05280602

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia A

    phase 1 mab completed

    1 trial

  23. PF-07038124 or vehicle

    Pfizer

    Healthy

    phase 1 small molecule completed

    1 trial

  24. PF-07868489 Placebo, PF-07868489

    Pfizer Australia Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule active

    1 trial

  25. PF614

    Ensysce Biosciences

    Healthy

    phase 1 small molecule completed

    1 trial

  26. PF614

    Ensysce Biosciences

    Recreational Drug Use

    phase 1 small molecule completed

    2 trials

  27. PF614

    Ensysce Biosciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  28. PF614 capsule

    Ensysce Biosciences

    Pharmacokinetics

    phase 1 small molecule active

    1 trial

  29. PF614 solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  30. PG-033

    Prime Medicine

    Lichen Simplex Chronicus

    phase 1 small molecule active

    1 trial

  31. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

  32. PH-ACP3GA-01/24

    Philogen S.p.A.

    Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  33. PH-ACP3GA-03/25

    Philogen S.p.A.

    Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  34. PH-CAIXGA-02/24

    Philogen S.p.A.

    Patients with suspected clear cell renal cell carcinoma (ccRCC)

    phase 1 other active

    1 trial

  35. PH-F8IL10INTRA-03/24

    Philogen S.p.A.

    Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

    phase 1 other active

    1 trial

  36. PH-FAPLU-02-23

    Philogen S.p.A.

    Patients with advanced/metastatic FAP-positive tumors

    phase 1 other active

    1 trial

  37. PH-L19IL2CORK-01/25

    Philogen S.p.A.

    Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

    phase 1 other active

    1 trial

  38. PIC1 Injection

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  39. PIPE-307

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    2 trials

  40. PIPE-791

    Contineum Therapeutics

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 1 small molecule completed

    1 trial

  41. PIPE-791

    Contineum Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  42. PIPE-791

    Contineum Therapeutics

    Chronic Osteoarthritis Pain

    phase 1 small molecule completed

    1 trial

  43. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  44. PKE LPSpilot

    United Therapeutics Europe Ltd

    Cardiovascular Disease

    phase 1 small molecule completed

    1 trial

  45. PKM23567

    Sanofi-aventis Healthcare Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  46. PL2200 fasted

    Protalix BioTherapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  47. PLATFORMPACAN1001

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  48. PLN-101095

    PLIANT THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.